Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NetraMark Holdings ( (TSE:AIAI) ) has provided an announcement.
NetraMark Holdings Inc. has entered into a contract with Asklepion Pharmaceuticals to apply its NetraAI platform in a Phase III pediatric cardiac study. This collaboration aims to leverage NetraAI’s advanced AI technology to analyze patient data and optimize trial outcomes by identifying patient subgroups that benefit most from treatment. The partnership underscores a commitment to innovation in pediatric drug development, with the goal of enhancing the understanding and efficacy of L-citrulline for children undergoing cardiopulmonary bypass surgery.
More about NetraMark Holdings
NetraMark Holdings Inc. is a leader in the development of Generative Artificial Intelligence and Machine Learning solutions specifically for the pharmaceutical industry. The company offers a unique topology-based algorithm that can segment patient data into subsets, enabling the use of various ML methods to transform data into intelligent insights. This capability allows for accurate disease segmentation and patient classification for drug sensitivity and treatment efficacy.
Average Trading Volume: 55,572
Technical Sentiment Signal: Buy
Current Market Cap: C$104.9M
For detailed information about AIAI stock, go to TipRanks’ Stock Analysis page.